CHICAGO (Reuters) -
Eli Lilly & Co (LLY.N) said on Friday
that it had won approval to market its blockbuster osteoporosis
drug to post-menopausal women who are at high risk for invasive
breast cancer.

The company also said U.S. health regulators had extended
the use of the drug, known as Evista, to help reduce the risk
of the aggressive form of breast cancer in post-menopausal
women who have the bone-thinning disease.

However, the drug will also contain a stronger warning of
side effects that can include death by stroke.

Evista, known generically as raloxifene, is already
approved for the prevention and treatment of osteoporosis, or
bone thinning, in post-menopausal women.

Lilly said Evista, like the hormone estrogen, helps to
fight osteoporosis. But Evista also blocks estrogen in breast
tissue, the drug maker said.

Sales of Evista, a selective estrogen receptor modulator,
topped $1 billion in 2006.

SERMs are drugs used to treat osteoporosis that also appear
to prevent breast cancer by reducing estrogen in breast tissue.
Estrogen in breast tissue can drive some types of breast
cancer.

“This data's been unfolding for the last few years, so it's
not as if physicians are not aware of this, but now Lilly will
be able to market it,” said Deutsche Bank analyst Barbara Ryan.

In 2007, Evista sales were flat with the prior year, she
noted. “Our view is that this (approval) may begin to deliver
some growth of maybe 10 to 20 percent,” she said.

That would equate to roughly $100 million to $200 million
in tadalafil alternative revenues annually. “But it doesn't brand tadalafil

move the needle at Lilly,” Ryan said. “So it's not momentous,
but we'll watch the scripts like everyone else, and maybe we'll
be surprised.”

Lilly, whose other products include tadalafil soft
Prozac
and erectile dysfunction drug Cialis, reported second-quarter
revenue of $4.63 billion.

Earlier this year, Lilly updated the label for Evista to
include safety information from a clinical trial that evaluated
post-menopausal women, some of whom were suffering from
coronary artery disease and some who were at increased risk for
coronary disease.

The trial found no increase in the incidence of stroke but
an increase in the incidence of death because of stroke.

Since the new label for Evista will include new uses and an
expanded patient population, Lilly has worked with the FDA to
revise the package insert. The insert will now emphasize that
women with an active or past history of venous generic tadalafil softtabs

– buy tadalafil cialis
deadly blood clots — should not take Evista and
that women at risk for stroke should receive the drug only
after careful evaluation.

A company spokeswoman said the so-called black-box warning
did not preclude the company from conducting direct-to-consumer
advertising.

The company presented studies of 37,000 women that compared
Evista with a placebo or tamoxifen, which has been used about
25 years to treat patients with advanced breast cancer.

Competing osteoporosis drugs include Merck & Co Inc's
(MRK.N) Fosamax, and Roche Holding AG's (ROG.VX) and
GlaxoSmithKline Plc's (GSK.L) Boniva.

Shares of Eli Lilly were down 33 cents at $56.85 in morning
New York Stock Exchange trade. Their price has ranged from
$51.13 to $60.63 during the past 52 weeks.

(Reporting by Debra Sherman)

WASHINGTON (Reuters) -
A Canadian study involving mice
shows that anti-impotence pills might protect the hearts of
people with a common form of muscular dystrophy, researchers
said on Monday.

Canadian researchers gave sildenafil, the active ingredient
in drug maker Pfizer Inc's Viagra, to mice with an animal
version of Duchenne muscular dystrophy, and found that it
improved their heart performance.

They said it would be premature to give Viagra to people
with the disease, but said the results indicate the drug
potentially could be used to prevent or delay heart failure in
children with Duchenne muscular dystrophy.

The mice were given doses of the drug comparable to those
administered to treat erectile dysfunction in men. The study,
published in the Proceedings of the National Academy of
Sciences, showed that sildenafil cut the levels of damage to
contracting heart muscle cells.

“If you don't give the sildenafil, the heart of these mice
doesn't function as well as normal mice, and they are more
susceptible to stress-induced cell death,” said researcher
Christine Des Rosiers of the Montreal Heart Institute.

She said in an interview the drug worked to improve heart
performance in the mice by preventing the breakdown of a
naturally occurring chemical. Called cyclic guanosine
tadalafil cialis from india, or cGMP, it is involved in a number of cellular
signaling pathways, the researchers said.

Other impotence drugs also affect the chemical cGMP,
including vardenafil, sold by Schering Plough under the brand
name Levitra, and tadalafil, sold by Eli Lilly and Co. under
the brand name Cialis.

Duchenne muscular dystrophy is an inherited wasting disease
soft tablet tadalafil
by weakness and progressive degeneration of the
muscles, including the heart muscle. It begins in the legs and
pelvis, and later affects the whole body. Most people with the
disease must use a wheelchair by about age 12.

It is caused by a genetic mutation of dystrophin, a protein
vital to muscle cells.

Heart problems can appear at around age 10 and they
progress quickly, affecting most people with the disease by age
20. These heart problems are an important cause of death among
patients with muscular dystrophy.

Sildenafil was developed as a heart drug and is widely
prescribed for erectile dysfunction as well as pulmonary
hypertension. The researchers said tadalafil funziona
are under way
about possible future studies using the drug in patients with
muscular dystrophy.

“There's a lot of information on this drug that shows it
appears to be relatively safe in adults,” Des Rosiers said,
while emphasizing that future human clinical trials are needed
before doctors prescribe it for heart trouble in these
patients. (Editing by Maggie Fox and Doina Chiacu)

NEW YORK (Reuters) -
Eli Lilly and Co. (LLY.N) on Tuesday
posted better-than-expected quarterly earnings and raised its
2007 forecast, helped by surging sales of its prescription
drugs, including depression treatment Cymbalta.

Lilly posted strong revenue gains from Cymbalta and Zyprexa
for buy cheap tadalafil
, which rose 67 percent and 9 percent,
softtabs tadalafil
, and helped the company beat revenue expectations
by about $250 million.

“Together these two products accounted for almost two
thirds of the revenue beat,” JPMorgan analyst Roberto Cuca
wrote in a research note. “This should boost sentiment among
those investors who had been concerned about the health of
Lilly's (central nervous system) franchise.”

The second-quarter results also signaled Lilly's
dipendenza tadalafil
of Icos in January is paying off, accounting for
about a third of the 20 percent jump in quarterly sales to
$4.63 billion. Through that deal, Lilly gained full ownership
of the widely used Cialis impotence pill, which posted a 26
percent rise in sales to $293 billion.

Lilly shares rose 2 percent in opening trade.

Excluding charges related to acquisitions of Hypnion Inc.
and Ivy Animal Health in the period, Lilly earned 90 cents per
share, which was 8 cents better than analysts had expected,
according to Reuters Estimates.

On a net basis after those charges, the Indianapolis-based
drug maker earned $664 million, or 61 cents per share, from
$822 million, or 76 cents per share, a year earlier.

Lilly forecast 2007 earnings per share, excluding special
items, of $3.40 to $3.50 per share, up from its previous
forecast of $3.29 to $3.39 per share. It expects sales to grow
in the “mid-teens” percentage range.

Cymbalta's revenue rise to $520 million in the second
quarter was helped by its new use against generalized anxiety
disorder approved by U.S. regulators in February.

Meanwhile Zyprexa, the company's biggest product, rebounded
with a 9 percent rise to $1.21 billion after earlier sales
declines prompted by concerns over its tendency to cause weight
gains.

Lilly said higher overseas sales of Zyprexa, along with
higher U.S. prices, outstripped lower U.S. demand for the
medicine. The company projected “modest” worldwide sales growth
of Zyprexa for the full year.

Gemzar, used to treat lung and pancreatic cancer, grew 15
percent to $396 million, while lung cancer treatment Alimta
jumped 35 percent to $207 million.

Sales of Strattera, used to treat attention deficit
vardenafil disorder, slipped one percent to $142 million,
amid concerns that such drugs pose heart risks and cause
tadalafil soft tablet
problems, such as hallucinations.

Eli Lilly shares rose $1.12 to $58.29 in opening trade on
the New York Stock Exchange. They are up 12 percent in 2007,
outpacing a 2 percent rise for the American Stock Exchange
Pharmaceutical index. (.DRG)

(Reporting by Ransdell Pierson and Lewis Krauskopf)

INDIANAPOLIS - Core medicines Zyprexa and Cymbalta helped Eli Lilly and Co. beat Wall Street’s second-quarter expectations, although profits fell 19 percent at the tadalafil funziona
company because of acquisition costs.

The drug maker’s earnings fell to $663.6 million, or 61 cents per share, from $822 million, or 76 cents per share, in the previous year. The results were dragged down 29 cents by the acquisitions of two companies, Hypnion Inc. and Ivy Animal Health Inc.

Excluding those charges, adjusted earnings totaled $978.7 million, or 90 cents per share. Analysts had expected 82 cents per share on that basis, according to Thomson Financial.

Lilly’s revenue topped forecasts as well, rising 20 percent to $4.63 billion. Analysts were expecting sales of $4.39 billion.

The jump was triggered in part by sales of the depression treatment Cymbalta, which surged 67 percent to $519.5 million. Lilly’s andrologia tadalafil
drug, the anti-psychotic Zyprexa, saw sales increase 9 percent to $1.2 billion.

“Sales were strong, so in terms of quality I think (the quarter) was very good,” said analyst Joseph Tooley of A.G. Edwards & Sons Inc.

Lilly raised its 2007 sales and profit guidance and is now ed pills
full-year adjusted earnings per share in the range of $3.40 to $3.50, or $2.75 to $2.85 per share on a reported basis. On average, analysts were seeking profit of $3.39 per share.

Lilly shares closed unchanged at $57.17.

Revenue from another top Lilly product, the erectile dysfunction drug Cialis, increased 26 percent to $293 million. Lilly now gets all the sales from that drug; previously it split the revenue with ICOS Corp., which it acquired this year.

The osteoporosis drug Evista saw slow growth, with sales rising 1 percent to $278 million. But it received a boost Tuesday when a U.S. Food and Drug Administration committee recommended its use to reduce the risk of invasive breast cancer for some women.

Cymbalta, Cialis and several other drugs launched this decade now comprise 32 percent of Lilly’s revenue total, reducing Lilly’s reliance on Zyprexa, which goes off patent in 2011.

“These products that they have launched are growing cialis comparison cost dosage effects experiencecheap forumcialis generic levitra lowcialis online open purchasecialis sidecialis viagra viagracialis vscialis westerncialis womancheap
… and they’re relatively early in their product life cycle,” Tooley said.

Company leaders also touted their product pipeline during a Tuesday conference call with analysts. President and Chief Operating Officer John Lechleiter said Lilly has had eight drugs enter early-stage clinical trial testing this year and expects to hit its goal of 15.

However, Miller Tabak and Co. analyst Les Funtleyder noted that drugs in early stages of development are too shaky to count on for future revenue.

“I still have some uncertainty about where the next couple of years worth of growth is going to come from,” he said. “I wish they had more in their late stage pipeline than they do.”

Confidence Inc. is recalling about 1,500 boxes of Long Weekend dietary supplements because representatives from the

Food and Drug Ed medicine

Food and Drug Administration found the product contains undeclared tadalafil, which makes the product an drug dysfunction erectile
drug. Tadalafil is a drug used to treat erectile cialis tadalafil generic rezeptfrei
. Tadalafil can interact with nitrates found in some prescription drugs and could lower blood pressure to dysfunction pill
levels. People with diabetes, high blood pressure, high erectile pill or heart disease often take nitrates, according to the FDA. No illnesses have been reported.

The product comes in three-capsule boxes. It was sold nationwide and in Puerto Rico, Canada, the United Kingdom, Russia and China. Details: by phone at 516-767-1870.

MailChimp.com identifies three innocent words not to use in an email subject line.

Atlanta, GA (PRWEB) October 2, 2007 — MailChimp conducted a study of its customers' email campaigns and found that some of the most harmless words can spell disaster when included in email subject lines. Because of bulging inboxes and an endless torrent of spam, the study found that readers treat new emails as guilty until proven innocent. The study concluded that if an email marketer wants their emails to get read, both by friends and business contacts, there are a few words that a marketer would be well served to avoid.

Based on the results of this study, MailChimp has created a list of the top 3 words to avoid in a subject line based on analysis of over 200 million emails:

Help
Never put the word “help” in the subject title. It may be like a crime in progress where passer-bys keep on walking, or maybe most readers have just reached their respective capacity to “help”, but most readers do not respond to this word. The reluctance to open “help” messages may also stem from well-known scams asking for tadalafil soft tab
. The most common source for these scams is Nigeria. You can read more about email scams in the New York Times.

% off
While it may be erectile dysfunction advices
, the stronger the commercial pitch in the subject line, the less likely it's going to be read. Consumers have had to become savvy in navigating their email inbox - as soon as an email smells like a sleazy offer, it's zapped with the delete button.

Reminder
Always avoid using the word “reminder” in the subject line. If a marketer needs to send out a reminder, MailChimp recommends avoiding the word “reminder” and, instead, communicate in the subject line that there is useful trattamento cronico tadalafil
inside that the reader is going to want. Analogous to “reminder” is repeating the same subject line for a particular event and sending out several emails in advance. The first email may get read, but after that it's splitsville.

The three innocuous words above are joining the rank of other all-too-popular spammy words like: Free, Sex, Cialis, etc. Not only will an email not get read if the subject line or body is peppered with these spam words, odds are it won't even get to the reader. And getting an HTML email to the targeted inbox has become even more of a challenge, thanks to firewalls and spam filters. The net result is an obliterated email that never gets to the intended recipient.

By avoiding the three words mentioned above, email marketers should be more successful in getting their intended audience to open their emails.

About this study

MailChimp analyzed over 200 million emails as part of this study looking at email open rates and subject lines. To read more about this study, as well as MailChimp's secret formula for writing the best email subject line, visit the MailChimp.com Resource Center.

About MailChimp

MailChimp provides do-it-yourself email marketing services worldwide to over 10,000 small businesses, design agencies, non-profits, restaurants, and e-Commerce sites. With MailChimp you can create tadalafil alternative
, eye-catching HTML emails in minutes. At MailChimp it's “Your Logo, Not Ours”. We do not add any marketing messages or logos to your email. Try out MailChimp's free trial to see how the Chimp can work for you.

###

MailChimp
Neil Bainton
404-551-2987
E-mail Information

Trackback URL: http://prweb.com/pingpr.php/UGlnZy1Mb3ZlLUluc2UtTWFnbi1UaGlyLVplcm8=

The Medicines and Healthcare Buy cialis soft
Agency (MHRA) said it was asking for the return of batch number 65542 of counterfeit Reductil 15mg.

The drugs were discovered within the UK supply chain, the second such discovery in recent days.

Last week, counterfeit Cialis capsules, used to treat erectile tadalafil online
, were also discovered.

Prior to that, the last discovery of counterfeit drugs in the UK supply chain was in 1994.

However, the leading drug company Pfizer recently warned of the dangers of fake drugs entering the legitimate system.

It said this could happen because of “parallel packaging” - where drugs made in one country are repackaged for another.

Concerns

The MHRA said that initial tests on the fake Reductil tablets did not indicate that it posed an immediate risk to patients.

It advised anyone who had the product with the batch number 65542 anywhere on the pack should return it to where it was obtained.

Professor Kent Woods, chief executive of the MHRA, said: “Although the quality of counterfeit medicines cannot be guaranteed, there is no indication from testing
of the counterfeit product that it poses an immediate risk to patients.

“If patients have any concerns about possible side effects they should discuss them with their doctor.”

The MHRA said that no batches manufactured and distributed by Abbott Laboratories Ltd, the licence holder of the authentic Reductil tablets, were affected by this recall and there was no concern with the Abbott product.

David Pruce, Director of Practice and Quality Improvement at the Royal Pharmaceutical Society of Great Britain, said: “We know that counterfeit medicines are a world-wide problem but prior to the identification of these two products, dysfunction erectile cure in the UK had been a rare occurrence.

“The society has been working with the MHRA through our team of Inspectors and we ask cialis levitra sildenafil tadalafil vardenafil viagra
s to co-operate with the MHRA’s investigation and to be alert for counterfeit medicines.”

He added: “Patients are advised to contact their doctor or pharmacist in the event of any concern.”

The following recalls have been announced:

_WhiteWave Foods Co. is recalling about 120,000 bottles of Silk Soymilk Chocolate Flavor because they might contain undeclared milk protein, which could cause a severe or life-threatening reaction in people who have milk protein allergies. Four people have had allergic reactions to the product and are now drug tadalafil
, said spokeswoman Marguerite Copel for the Mount Crawford, Va., company. The recalled 11-ounce generic soft tab cialis
bottles, which were distributed nationwide, have the use-by date of May 7 this year. For more information, consumers can call 800-587-2259.

_KG Enterprises LLC is recalling Maxidus supplements, because they may contain active ingredients of FDA-regulated erectile dysfunction drugs that are not declared on the packaging. Samples of the Maxidus supplements contained sildenafil and tadalafil, which could interact with nitrates found in some prescription drugs for diabetes, high blood pressure, high cholesterol or heart disease. If the active drug ingredients interact with nitrates, it could cause blood pressure to drop to dangerous levels.

The Tadalafil funziona
Maxidus pills were sold online and via mail order until December 2007. They were sold in 10-capsule blister packs inside gold boxes. Details: by phone at 866-373-2488.